Daily Respiratory Research Analysis
Three high-impact studies advance respiratory science and care: (1) human lung mucosal SARS-CoV-2–specific T cells in bronchoalveolar spaces are robust, correlate with better respiratory outcomes, and persist as polyfunctional resident memory; (2) severe primary ciliary dyskinesia arises from undocking of the multiciliary network with proteostasis stress and cell-fate switching, extending disease mechanisms beyond motility defects; (3) a Cochrane living review confirms nicotine e-cigarettes incr
Summary
Three high-impact studies advance respiratory science and care: (1) human lung mucosal SARS-CoV-2–specific T cells in bronchoalveolar spaces are robust, correlate with better respiratory outcomes, and persist as polyfunctional resident memory; (2) severe primary ciliary dyskinesia arises from undocking of the multiciliary network with proteostasis stress and cell-fate switching, extending disease mechanisms beyond motility defects; (3) a Cochrane living review confirms nicotine e-cigarettes increase long-term smoking cessation versus NRT, informing tobacco control policy.
Research Themes
- Mucosal immunity and resident memory T cells in the human lung
- Ciliopathy mechanisms: proteostasis and multiciliary network integrity in airway disease
- Tobacco cessation strategies and population respiratory health
Selected Articles
1. Undocking of an extensive ciliary network induces proteostasis and cell fate switching resulting in severe primary ciliary dyskinesia.
This mechanistic study shows that CCDC39/CCDC40 variants disrupt docking of the multiciliary network, triggering proteostasis stress and cell fate switching in multiciliated airway cells, offering an explanation for severe primary ciliary dyskinesia beyond motility loss. The work reframes PCD as a ciliopathy involving structural-network failure and proteostatic responses.
Impact: It identifies a non-motility mechanism for severe PCD, opening new avenues for diagnostics and therapies targeting proteostasis and ciliary anchoring. The translational framing in human systems raises broad interest in airway ciliopathies.
Clinical Implications: Clinicians should consider that severe PCD phenotypes may reflect proteostasis and epithelial cell fate alterations; biomarkers of proteotoxic stress and imaging of ciliary network integrity could refine diagnosis and stratification.
Key Findings
- CCDC39/CCDC40 variants cause undocking of the multiciliary network in human multiciliated cells.
- Proteostasis stress responses are activated, linking structural failure to cellular dysfunction.
- Cell fate switching accompanies ciliary network disruption, explaining severe PCD beyond motility loss.
Methodological Strengths
- Human disease-relevant cell systems interrogating specific pathogenic variants
- Mechanistic linkage from structural phenotype to proteostasis and fate changes
Limitations
- Abstract indicates cellular systems; in vivo validation and longitudinal patient data are not detailed
- Quantitative prevalence and generalizability across PCD genotypes require further study
Future Directions: Validate proteostasis biomarkers in patient cohorts, test modulators of ciliary anchoring and proteostasis as therapeutic candidates, and map timelines of fate switching in airway epithelium in vivo.
Primary ciliary dyskinesia is a rare monogenic syndrome that is associated with chronic respiratory disease, infertility, and laterality defects. Although more than 50 genes causative of primary ciliary dyskinesia have been identified, variants in the genes encoding coiled-coil domain-containing 39 (CCDC39) and CCDC40 in particular cause severe disease that is not explained by loss of ciliary motility alone. Here, we sought to understand the consequences of these variants on cellular functions beyond impaired motility. We used human cells with pathogenic variants in
2. Robust mucosal SARS-CoV-2-specific T cells effectively combat COVID-19 and establish polyfunctional resident memory in patient lungs.
In 159 COVID-19 patients, single-cell profiling revealed robust, polyfunctional SARS-CoV-2–specific T cells in BALF that correlate with lower viral loads and better respiratory metrics, distinct from blood T cells. These cells persist as tissue-resident memory after clearance, underscoring mucosal T cell roles in protection and recovery.
Impact: Defines lung-resident antiviral T cell features in humans with direct clinical correlations, informing mucosal vaccine design and biomarkers for disease monitoring.
Clinical Implications: Supports strategies to elicit mucosal T cell immunity (e.g., intranasal vaccines) and suggests BALF T cell profiling could aid prognosis and recovery assessments.
Key Findings
- SARS-CoV-2–specific T cells are robustly induced in BALF regardless of prior vaccination.
- BALF T cell polyfunctionality and glycolysis signatures correlate with lower viral loads and better respiratory function.
- After viral clearance, BALF SARS-CoV-2–specific T cells persist as polyfunctional tissue-resident memory.
Methodological Strengths
- Integrated single-cell transcriptomics with paired BALF–blood sampling in humans
- Direct correlation of immune phenotypes with clinical virologic and physiologic outcomes
Limitations
- Observational design limits causal inference on protection mechanisms
- BALF sampling may select for hospitalized or procedurally eligible patients
Future Directions: Test whether intranasal or mucosal vaccines enhance similar BALF T cell profiles and validate minimally invasive surrogates for mucosal immunity.
Mucosal antigen-specific T cells are pivotal for pathogen clearance and immune modulation in respiratory infections. Dysregulated T cell responses exacerbate coronavirus disease 2019 severity, marked by cytokine storms and respiratory failure. Despite extensive description in peripheral blood, the characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cells in the lungs remain elusive. Here we conducted integrated single-cell profiling of SARS-CoV-2-specific T cells in 122 bronchoalveolar lavage fluid (BALF) and 280 blood samples from 159 patients, including 27 paired BALF and blood samples from 24 patients. SARS-CoV-2-specific T cells were robustly elicited in BALF irrespective of prior vaccination, correlating with diminished viral loads, lessened systemic inflammation and improved respiratory function. SARS-CoV-2-specific T cells in BALF exhibited profound activation, along with proliferative and multi-cytokine-producing capabilities and a glycolysis-driven metabolic signature, which were distinct from those observed in peripheral blood mononuclear cells. After viral clearance, these specific T cells maintained a polyfunctional tissue-resident memory phenotype, highlighting their critical roles in infection control and long-term protection.
3. Electronic cigarettes for smoking cessation.
In this living Cochrane review (90 completed studies; 49 RCTs; 29,044 participants), nicotine e-cigarettes increase long-term quit rates versus NRT (RR 1.59, 95% CI 1.30–1.93) and versus non-nicotine ECs. Serious adverse events were rare with no clear excess versus comparators; however, longer, larger trials are needed to fully assess safety.
Impact: Provides high-certainty evidence that informs clinical guidelines and regulation for smoking cessation—central to reducing chronic respiratory disease burden.
Clinical Implications: Offer nicotine e-cigarettes as a cessation option alongside NRT and behavioral support, while counseling on regulated products and the need for follow-up given limited long-term safety data.
Key Findings
- Nicotine e-cigarettes increase quit rates versus NRT (high-certainty) and versus non-nicotine e-cigarettes (moderate-certainty).
- Serious adverse events were rare across study arms; no clear difference versus NRT or non-nicotine ECs.
- Evidence for AEs is imprecise and long-term safety needs longer, larger RCTs; illicit/THC products may have different harm profiles.
Methodological Strengths
- Cochrane methodology with GRADE certainty assessments and network/meta-analyses
- Broad evidence base including 49 RCTs and 29,044 participants
Limitations
- Imprecision remains due to limited number of high-quality RCTs with low event rates
- Long-term safety beyond 6–12 months is not fully established
Future Directions: Conduct long-duration, adequately powered RCTs to evaluate long-term safety, sustained abstinence, and head-to-head comparisons with combined pharmacotherapies.
BACKGROUND: Electronic cigarettes (ECs) are handheld electronic vaping devices that produce an aerosol by heating an e-liquid. People who smoke, healthcare providers, and regulators want to know if ECs can help people quit smoking, and if they are safe to use for this purpose. This is a review update conducted as part of a living systematic review. OBJECTIVES: To examine the safety, tolerability, and effectiveness of using EC to help people who smoke tobacco achieve long-term smoking abstinence, in comparison to non-nicotine EC, other smoking cessation treatments, and no treatment. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and PsycINFO to 1 February 2024 and the Cochrane Tobacco Addiction Group's Specialized Register to 1 February 2023, reference-checked, and contacted study authors. SELECTION CRITERIA: We included trials randomizing people who smoke to an EC or control condition. We included uncontrolled intervention studies in which all participants received an EC intervention. Studies had to report an eligible outcome. DATA COLLECTION AND ANALYSIS: We followed standard Cochrane methods for screening and data extraction. We used the risk of bias tool (RoB 1) and GRADE to assess the certainty of evidence. Critical outcomes were abstinence from smoking after at least six months, adverse events (AEs), and serious adverse events (SAEs). Important outcomes were biomarkers, toxicants/carcinogens, and longer-term EC use. We used a fixed-effect Mantel-Haenszel model to calculate risk ratios (RRs) with a 95% confidence interval (CI) for dichotomous outcomes. For continuous outcomes, we calculated mean differences. Where appropriate, we pooled data in pairwise and network meta-analyses (NMA. AUTHORS' CONCLUSIONS: There is high-certainty evidence that ECs with nicotine increase quit rates compared to NRT and moderate-certainty evidence that they increase quit rates compared to ECs without nicotine. Evidence comparing nicotine EC with usual care or no treatment also suggests benefit, but is less certain due to risk of bias inherent in the study design. Confidence intervals were, for the most part, wide for data on AEs, SAEs, and other safety markers, with no evidence for a difference in AEs between nicotine and non-nicotine ECs nor between nicotine ECs and NRT, but low-certainty evidence for increased AEs compared with behavioural support/no support. Overall incidence of SAEs was low across all study arms. We did not detect evidence of serious harm from nicotine EC, but longer, larger studies are needed to fully evaluate EC safety. Our included studies tested regulated nicotine-containing EC; illicit products and/or products containing other active substances (e.g. tetrahydrocannabinol (THC)) may have different harm profiles. The main limitation of the evidence base remains imprecision due to the small number of RCTs, often with low event rates. Further RCTs are underway. To ensure the review continues to provide up-to-date information to decision-makers, this is a living systematic review. We run searches monthly, with the review updated when relevant new evidence becomes available. Please refer to the Cochrane Database of Systematic Reviews for the review's current status.